OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Tzachanis on the Likelihood of Cure With CAR T-Cell Therapy in Lymphoma

July 13th 2020

Dimitrios Tzachanis, MD, PhD, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.

Dr. Pennell on Challenges With NGS in Lung Cancer

July 10th 2020

Nathan Pennell, MD, PhD, discusses challenges with next-generation sequencing in lung cancer.

Dr. Sartor on the Significance of the REASSURE Trial in mCRPC

July 10th 2020

Oliver Sartor, MD, discusses the significance of the REASSURE trial in patients with metastatic castration-resistant prostate cancer.

Dr. Daver on Updated Findings With Magrolimab/Azacitidine in MDS

July 10th 2020

Naval G. Daver, MD, discusses updated findings on the combination of the investigational CD47-directed antibody magrolimab and azacitidine in myelodysplastic syndrome.

Dr. Rudin on the Design of the KEYNOTE-604 Trial in ES-SCLC

July 9th 2020

Charles M. Rudin, MD, PhD, discusses the design of the phase 3 KEYNOTE-604 trial in extensive-stage small cell lung cancer.

Dr. Halmos on the Importance of Identifying Biomarkers in Advanced NSCLC

July 9th 2020

Balazs Halmos, MD, MS, discusses the importance of identifying biomarkers in advanced non–small cell lung cancer.

Dr. Eggermont on Responses to Adjuvant Pembrolizumab in Stage III Melanoma Subtypes

July 9th 2020

Alexander M. M. Eggermont, MD, PhD, discusses responses to adjuvant pembrolizumab in patients with different subtypes of stage III melanoma.

Dr. Morris on the Design of the Phase 3 CONDOR Trials in Recurrent Prostate Cancer

July 9th 2020

Michael J. Morris, MD, discusses the design of the phase 3 CONDOR trial in men with biochemically recurrent prostate cancer.

Dr. Lin on Developing Systemic Therapies for Patients with Brain Metastases in HER2+ Breast Cancer

July 9th 2020

Nancy U. Lin, MD, discusses the development of systemic therapies for the treatment of patients with metastatic HER2-positive breast cancer and brain metastases.

Dr. Ghia on Efficacy and Safety of Acalabrutinib in Relapsed/Refractory CLL

July 9th 2020

Paolo Ghia, MD, PhD, discusses the efficacy and safety of acalabrutinib in the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Dr. Roué on Interest With TG-1701 in Ibrutinib-Resistant MCL Models

July 9th 2020

Gaël Roué, PhD, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma.

Dr. Leslie on the Benefits With Zanubrutinib in MCL

July 9th 2020

Lori A. Leslie, MD, discusses the benefits with zanubrutinib (Brukinsa) in the treatment of patients with mantle cell lymphoma.

Dr. Weisel on Interim Analysis With Isatuximab Plus KRd in High-Risk Myeloma

July 9th 2020

Katja Weisel, MD, discusses the interim analysis of the phase 2 GMMG-Concept trial with isatuximab-irfc in combination with carfilzomib, lenalidomide, and dexamethasone in high-risk patients with newly diagnosed multiple myeloma.

Dr. Katz on Redefining Risk Stratification in Prostate Cancer

July 9th 2020

Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.

Dr. Davids on Updated Data With Ibrutinib/Umbralisib in R/R CLL and MCL

July 8th 2020

Matthew S. Davids, MD, MMSc, discusses updated findings from a phase 1/1b study which examined the combination of ibrutinib (Imbruvica) and umbralisib in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Berdeja on Dosing JNJ-4528 in Relapsed/Refractory Multiple Myeloma

July 8th 2020

Jesus G. Berdeja, MD, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with relapsed/refractory multiple myeloma.

Dr. Shore on Benefits of Immunotherapy INO-5150 in Recurrent Prostate Cancer

July 8th 2020

Neal D. Shore, MD, FACS, discusses the potential benefits of the immunotherapy INO-5150 for patients with biochemically recurrent prostate cancer.

Dr. Bekaii-Saab on Second-Line Treatment Options in HCC

July 8th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses second-line treatment options in hepatocellular carcinoma.

Dr. Jonasch on the Safety Profile of MK-6482 in Von Hippel-Lindau Disease–Associated RCC

July 8th 2020

Eric Jonasch, MD, discusses the safety profile of the investigational oral hypoxia-inducible factor-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC

July 8th 2020

Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.